 Chemotherapy metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma cisplatin bleomycin fluorouracil nasopharyngeal carcinoma UCNT radiosensitive chemosensitive latter phase II methodology intensive work-up patients recurrent REC metastatic MTS UCNT monthly cycles cisplatin CDDP day mg IV day continuous infusion CI days CI days PBF patients North African sex ratio males female median World Health Organization WHO performance status patients assessable response complete responses CRs partial responses PRs overall response rate confidence interval assessable group global rate CRs group previous chemotherapy patients CR chemotherapy group patients patients alive evidence disease months bone MTS radiation therapy sites results chemosensitivity UCNT observation unmaintained long-term responders curability possible consideration